Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose naltrexone and liver function safety

M A Marrazzi1, J M Wroblewski, J Kinzie

  • 1Department of Psychiatry, Harper-Grace Hospitals, Detroit, MI, USA.

The American Journal on Addictions
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens.

Lung cancer (Amsterdam, Netherlands)·2001
Same author

Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy.

The American journal of gastroenterology·2001
Same author

Folic acid inhibition of EGFR-mediated proliferation in human colon cancer cell lines.

The American journal of physiology·1999
Same author

Adenoviral vectors in hematology: purging, stem cell gene transfer, or both.

Blood·1997
Same author

Anorexia nervosa presenting as a somatic delusional disorder responsive to pharmacotherapy.

The Journal of the American Osteopathic Association·1997
Same author

Adenoviral vectors efficiently target cell lines derived from selected lymphocytic malignancies, including anaplastic large cell lymphoma and Hodgkin's disease.

Clinical cancer research : an official journal of the American Association for Cancer Research·1997
Same journal

Rural-urban residence in relation to cannabis use influences and behaviors among a sample of US young adults reporting past-month cannabis use.

The American journal on addictions·2026
Same journal

Interpreting divergent mortality outcomes in veterans with substance use disorder and adverse social determinants of health.

The American journal on addictions·2026
Same journal

Do motives for and contexts of cannabis use interact to predict heavy cannabis use at the event-level?

The American journal on addictions·2026
Same journal

Risks of alcohol-energy drink co-consumption: Patterns, correlates and psychological outcomes in youth.

The American journal on addictions·2026
Same journal

Brief report: A cross-sectional survey of provider engagement with family members following patient drug overdose death.

The American journal on addictions·2026
Same journal

Brief Report: Is once daily enough? Assessing the impact of timing of methadone dose on pain sensitivity via quantitative sensory testing in persons with opioid use disorder.

The American journal on addictions·2026
See all related articles

High-dose naltrexone (Naltrexone) is safe for treating eating disorders. This study found no adverse liver function changes in patients receiving high-dose naltrexone therapy.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Psychiatry

Background:

  • Naltrexone is used for conditions beyond opiate addiction, like alcoholism and eating disorders, where endogenous opioids are implicated.
  • Some studies utilize high naltrexone doses (100-200 mg twice daily).
  • Prior research indicated potential liver enzyme elevations with very high doses (300 mg/day).

Purpose of the Study:

  • To assess the safety of high-dose naltrexone on liver function in patients with eating disorders.
  • To evaluate liver function parameters during a double-blind, crossover trial and an open-label period of naltrexone therapy.

Main Methods:

  • A double-blind, crossover trial using naltrexone at 100 mg twice daily.
  • Followed by an open-label period with naltrexone at 200 mg twice daily.

Related Experiment Videos

  • Monitoring of various liver function parameters throughout the study.

    • Main Results:

    • No clinically significant adverse changes in liver function were observed.
    • Laboratory liver function tests remained within normal limits.
    • Patients tolerated high-dose naltrexone therapy well.

    Conclusions:

    • High-dose naltrexone therapy (up to 200 mg twice daily) appears safe for individuals with eating disorders.
    • Naltrexone does not adversely affect liver function in this patient population at the studied doses.
    • Further research can explore naltrexone's efficacy in treating eating disorders with monitored liver function.